Literature DB >> 348113

Papulonecrotic tuberculid secondary to Mycobacterium bovis.

D L Iden, R S Rogers, A L Schroeter.   

Abstract

A patient with papulonecrotic tuberculid had a pruritic papular eruption associated with constitutional symptoms. The eruption flared whenever the patient received low doses of prednisone to control symptoms of temporal arteritis. A cervical lymph node biopsy specimen demonstrated acid-fast bacilli, and Mycobacterium bovis grew on the cultures. The eruption cleared completely with antituberculous therapy. This case demonstrated the clinicopathologic findings compatible with a diagnosis of papulonecrotic tuberculid. Skepticism regarding the existence of papulonecrotic tuberculid is probably a result of the current decreased prevalence of untreated tuberculosis, and the subsequently increased rarity of this entity.

Entities:  

Mesh:

Year:  1978        PMID: 348113

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  A common but underreported entity of papulonecrotic tuberculid.

Authors:  Preema Sinha; Anamika Sinha; Sukriti Baveja; Aradhana Sood
Journal:  Med J Armed Forces India       Date:  2014-08-04

2.  Moyamoya syndrome in a known case of pulmonary tuberculosis.

Authors:  Fahmi Yousef Khan; Hussain Kamal; Rania Musa; Ahmed Hayati
Journal:  J Neurosci Rural Pract       Date:  2010-07

3.  Papulonecrotic tuberculid-clinicopathologic and molecular features of 12 Indian patients.

Authors:  Rajalakshmi Tirumalae; Inchara K Yeliur; Meryl Antony; Geojith George; John Kenneth
Journal:  Dermatol Pract Concept       Date:  2014-04-30

4.  Lewandowsky's Rosaceiform Eruption: a Form of Cutaneous Tuberculosis Confirmed by PCR in Two Patients.

Authors:  Rodrigo Conlledo; Antonio Guglielmetti; Macarena Sobarzo; Francisca Woolvett; Francisca Bravo; Sergio González; Félix Fich; Verónica Vial
Journal:  Dermatol Ther (Heidelb)       Date:  2014-12-18

5.  Mycobacteria and the skin.

Authors:  J M Grange
Journal:  Int J Dermatol       Date:  1982-11       Impact factor: 2.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.